Effectiveness of vitamin D2 supplementation on high-sensitivity C-reactive protein and other metabolic indices in menopausal Thai women: a randomized-controlled trial
Issued Date
2022-01-01
Resource Type
ISSN
09513590
eISSN
14730766
Scopus ID
2-s2.0-85118292472
Pubmed ID
34704877
Journal Title
Gynecological Endocrinology
Volume
38
Issue
1
Start Page
83
End Page
89
Rights Holder(s)
SCOPUS
Bibliographic Citation
Gynecological Endocrinology Vol.38 No.1 (2022) , 83-89
Suggested Citation
Indhavivadhana S., Boonyachan W., Rattanachaiyanont M., Wongwananuruk T., Techatraisak K., Sa-nga-areekul N. Effectiveness of vitamin D2 supplementation on high-sensitivity C-reactive protein and other metabolic indices in menopausal Thai women: a randomized-controlled trial. Gynecological Endocrinology Vol.38 No.1 (2022) , 83-89. 89. doi:10.1080/09513590.2021.1988560 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83947
Title
Effectiveness of vitamin D2 supplementation on high-sensitivity C-reactive protein and other metabolic indices in menopausal Thai women: a randomized-controlled trial
Author's Affiliation
Other Contributor(s)
Abstract
Objective: To investigate the effectiveness of vitamin D2 supplementation with ergocalciferol on high-sensitivity C-reactive protein (hsCRP) level and other cardio-metabolic indices in menopausal Thai women. Materials and methods: A double-blind, randomized, placebo-controlled trial was conducted at the menopause clinic of a university hospital in Thailand from May 2017 to 2018. Participants were 80 postmenopausal women randomly assigned to treatment (N = 40, receiving vitamin D2 40,000 IU/week) or control (N = 40, receiving placebo) for 12 weeks. The primary outcome was hsCRP level, and secondary outcomes were cardio-metabolic profiles and 10-year risk of developing cardiovascular disease using the Framingham risk score. The changes from baseline to week-12 (Δ) of all outcomes were analyzed using a modified intention-to-treat (ITT) population. Results: The vitamin D2 (N = 39) and placebo (N = 37) groups were comparable in all baseline characteristics. The hsCRP level was significantly reduced in the vitamin D2 group (Δ of −0.39 ± 1.30 mg/L, p =.024) but not in the placebo group (Δ of −0.15 ± 1.15 mg/L, p =.521). However, the Δ of hsCRP had no statistical difference between groups; neither did the Δ of other cardio-metabolic parameters. Conclusion: In menopausal Thai women, vitamin D2 supplementation with ergocalciferol 40,000 IU/week for 12 weeks can reduce hsCRP level; and the treatment might be superior to placebo. However, the hsCRP levels after 12 weeks between both groups were not statistically different. Clinical Trial Registration: Thai Clinical Trials Registry (TCTR20161216001).